Semaglutide Pen
Approved
Semaglutide Pen is one of 2 therapeutic programs targeting Kidney Disease, Chronic. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
1
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
3 competitors in Kidney Disease, Chronic
#DrugCompanyPhaseTrials
1Jardiance
Boehringer IngelheimPhase 3
Semaglutide Pen
UUnity Health Toronto
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Semaglutide Pen. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Approved[1]
- Company
- UUnity Health Toronto